Topic Archives: Exelixis (EXEL)

Comments

  • An excellent exegesis of excecrable Navellierian exaggeration. I also owned it way back then, and after losing some mone...

  • I bought $EXEL a few years ago for $11 and change left it alone unil they had a viable product, just sold it when it hit...

  • $EXEL Doc, thanks for your summation. If you expect failure in the HCC trial that's reason enough for me not to pull th...

  • Dr. KSS MD PhD

    I'll have a crack at it. It's hard to justify covering, and logging research hours poking into, companies where we see n...

  • $EXEL,$BMY Exelixis and Bristol-Myers are two companies that have gotten relatively scant attention here over the years...

  • $AUPH: My hometown is Melbourne, maybe I should go on a reconnaissance mission as an attach√©-for the Gummune. Do you ne...

  • Ophad Hammer blog on $ESPR, $TRVN,$EXEL, $ARGL. Very long ESPR, long EXEL http://www.orf-blog.com/biotech-portfolio-u...

  • $EXEL #RCC $EXEL and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Thera...

  • Below is an interesting blog article - another affirmation and salutation to Dr. KSS's biotech vision: "2016 Biotech ...

  • $EXEL Don't want to steal your time - but do you have a quick opinion about exelixis and its recent mighty run? Haven...

  • $EXEL - From SA: http://seekingalpha.com/news/3187291-exelixis-cabometyx-superior-novartis-afinitor-extending-survival-k...

  • Thank you for the information. I do not own any $EXEL now, but did, and was wondering if would be a good repurchase. I...

  • Dr. KSS MD PhD

    Someone was asking about Exelixis in the context of its pursuing approval for cabozantinib for renal cell cancer. Keep i...

  • $EXEL My questions are How much would Cabozantinib add to the bottom line per share given that Novartis is in this ...

  • Dr. KSS, MD PhD

    Expect heavy selling pressure on small cap bio in wake of today's $EXEL brouhaha. $EXEL will be down 50 per cent. Probab...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.